Cargando…
Hypothesis-Driven, Structure-Based Design in Photopharmacology: The Case of eDHFR Inhibitors
[Image: see text] Photopharmacology uses light to regulate the biological activity of drugs. This precise control is obtained through the incorporation of molecular photoswitches into bioactive molecules. A major challenge for photopharmacology is the rational design of photoswitchable drugs that sh...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958501/ https://www.ncbi.nlm.nih.gov/pubmed/35258959 http://dx.doi.org/10.1021/acs.jmedchem.1c01962 |
_version_ | 1784676957096509440 |
---|---|
author | Kobauri, Piermichele Galenkamp, Nicole S. Schulte, Albert M. de Vries, Jisk Simeth, Nadja A. Maglia, Giovanni Thallmair, Sebastian Kolarski, Dušan Szymanski, Wiktor Feringa, Ben L. |
author_facet | Kobauri, Piermichele Galenkamp, Nicole S. Schulte, Albert M. de Vries, Jisk Simeth, Nadja A. Maglia, Giovanni Thallmair, Sebastian Kolarski, Dušan Szymanski, Wiktor Feringa, Ben L. |
author_sort | Kobauri, Piermichele |
collection | PubMed |
description | [Image: see text] Photopharmacology uses light to regulate the biological activity of drugs. This precise control is obtained through the incorporation of molecular photoswitches into bioactive molecules. A major challenge for photopharmacology is the rational design of photoswitchable drugs that show light-induced activation. Computer-aided drug design is an attractive approach toward more effective, targeted design. Herein, we critically evaluated different structure-based approaches for photopharmacology with Escherichia coli dihydrofolate reductase (eDHFR) as a case study. Through the iterative examination of our hypotheses, we progressively tuned the design of azobenzene-based, photoswitchable eDHFR inhibitors in five design–make–switch–test–analyze cycles. Targeting a hydrophobic subpocket of the enzyme and a specific salt bridge only with the thermally metastable cis-isomer emerged as the most promising design strategy. We identified three inhibitors that could be activated upon irradiation and reached potencies in the low-nanomolar range. Above all, this systematic study provided valuable insights for future endeavors toward rational photopharmacology. |
format | Online Article Text |
id | pubmed-8958501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-89585012022-03-29 Hypothesis-Driven, Structure-Based Design in Photopharmacology: The Case of eDHFR Inhibitors Kobauri, Piermichele Galenkamp, Nicole S. Schulte, Albert M. de Vries, Jisk Simeth, Nadja A. Maglia, Giovanni Thallmair, Sebastian Kolarski, Dušan Szymanski, Wiktor Feringa, Ben L. J Med Chem [Image: see text] Photopharmacology uses light to regulate the biological activity of drugs. This precise control is obtained through the incorporation of molecular photoswitches into bioactive molecules. A major challenge for photopharmacology is the rational design of photoswitchable drugs that show light-induced activation. Computer-aided drug design is an attractive approach toward more effective, targeted design. Herein, we critically evaluated different structure-based approaches for photopharmacology with Escherichia coli dihydrofolate reductase (eDHFR) as a case study. Through the iterative examination of our hypotheses, we progressively tuned the design of azobenzene-based, photoswitchable eDHFR inhibitors in five design–make–switch–test–analyze cycles. Targeting a hydrophobic subpocket of the enzyme and a specific salt bridge only with the thermally metastable cis-isomer emerged as the most promising design strategy. We identified three inhibitors that could be activated upon irradiation and reached potencies in the low-nanomolar range. Above all, this systematic study provided valuable insights for future endeavors toward rational photopharmacology. American Chemical Society 2022-03-08 2022-03-24 /pmc/articles/PMC8958501/ /pubmed/35258959 http://dx.doi.org/10.1021/acs.jmedchem.1c01962 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Kobauri, Piermichele Galenkamp, Nicole S. Schulte, Albert M. de Vries, Jisk Simeth, Nadja A. Maglia, Giovanni Thallmair, Sebastian Kolarski, Dušan Szymanski, Wiktor Feringa, Ben L. Hypothesis-Driven, Structure-Based Design in Photopharmacology: The Case of eDHFR Inhibitors |
title | Hypothesis-Driven,
Structure-Based Design in Photopharmacology:
The Case of eDHFR Inhibitors |
title_full | Hypothesis-Driven,
Structure-Based Design in Photopharmacology:
The Case of eDHFR Inhibitors |
title_fullStr | Hypothesis-Driven,
Structure-Based Design in Photopharmacology:
The Case of eDHFR Inhibitors |
title_full_unstemmed | Hypothesis-Driven,
Structure-Based Design in Photopharmacology:
The Case of eDHFR Inhibitors |
title_short | Hypothesis-Driven,
Structure-Based Design in Photopharmacology:
The Case of eDHFR Inhibitors |
title_sort | hypothesis-driven,
structure-based design in photopharmacology:
the case of edhfr inhibitors |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958501/ https://www.ncbi.nlm.nih.gov/pubmed/35258959 http://dx.doi.org/10.1021/acs.jmedchem.1c01962 |
work_keys_str_mv | AT kobauripiermichele hypothesisdrivenstructurebaseddesigninphotopharmacologythecaseofedhfrinhibitors AT galenkampnicoles hypothesisdrivenstructurebaseddesigninphotopharmacologythecaseofedhfrinhibitors AT schultealbertm hypothesisdrivenstructurebaseddesigninphotopharmacologythecaseofedhfrinhibitors AT devriesjisk hypothesisdrivenstructurebaseddesigninphotopharmacologythecaseofedhfrinhibitors AT simethnadjaa hypothesisdrivenstructurebaseddesigninphotopharmacologythecaseofedhfrinhibitors AT magliagiovanni hypothesisdrivenstructurebaseddesigninphotopharmacologythecaseofedhfrinhibitors AT thallmairsebastian hypothesisdrivenstructurebaseddesigninphotopharmacologythecaseofedhfrinhibitors AT kolarskidusan hypothesisdrivenstructurebaseddesigninphotopharmacologythecaseofedhfrinhibitors AT szymanskiwiktor hypothesisdrivenstructurebaseddesigninphotopharmacologythecaseofedhfrinhibitors AT feringabenl hypothesisdrivenstructurebaseddesigninphotopharmacologythecaseofedhfrinhibitors |